CA3195103A1 - Treatment of non-alcoholic steatohepatitis (nash) - Google Patents

Treatment of non-alcoholic steatohepatitis (nash)

Info

Publication number
CA3195103A1
CA3195103A1 CA3195103A CA3195103A CA3195103A1 CA 3195103 A1 CA3195103 A1 CA 3195103A1 CA 3195103 A CA3195103 A CA 3195103A CA 3195103 A CA3195103 A CA 3195103A CA 3195103 A1 CA3195103 A1 CA 3195103A1
Authority
CA
Canada
Prior art keywords
salt
25hc3s
day
nash
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3195103A
Other languages
English (en)
French (fr)
Inventor
Weiqi Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of CA3195103A1 publication Critical patent/CA3195103A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA3195103A 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash) Pending CA3195103A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029361P 2020-05-22 2020-05-22
US63/029,361 2020-05-22
US202063030207P 2020-05-26 2020-05-26
US63/030,207 2020-05-26
US202063113116P 2020-11-12 2020-11-12
US63/113,116 2020-11-12
US202163146555P 2021-02-05 2021-02-05
US63/146,555 2021-02-05
PCT/US2021/033743 WO2021237143A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (1)

Publication Number Publication Date
CA3195103A1 true CA3195103A1 (en) 2021-11-25

Family

ID=78707644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3195103A Pending CA3195103A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Country Status (11)

Country Link
US (1) US20230181601A1 (enExample)
EP (1) EP4153164A4 (enExample)
JP (1) JP2023527153A (enExample)
KR (1) KR20230015939A (enExample)
CN (1) CN115916181A (enExample)
AU (1) AU2021273936A1 (enExample)
BR (1) BR112022022737A2 (enExample)
CA (1) CA3195103A1 (enExample)
MX (1) MX2022014575A (enExample)
TW (1) TW202210081A (enExample)
WO (1) WO2021237143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026781A1 (en) 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
WO2013040324A1 (en) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
JP6442412B2 (ja) * 2013-03-15 2018-12-19 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
KR102462275B1 (ko) * 2016-08-02 2022-11-01 듀렉트 코퍼레이션 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
WO2018026781A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
US10980810B2 (en) * 2017-10-06 2021-04-20 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor

Also Published As

Publication number Publication date
WO2021237143A1 (en) 2021-11-25
BR112022022737A2 (pt) 2023-01-31
CN115916181A (zh) 2023-04-04
EP4153164A4 (en) 2024-06-26
EP4153164A1 (en) 2023-03-29
MX2022014575A (es) 2022-12-15
KR20230015939A (ko) 2023-01-31
US20230181601A1 (en) 2023-06-15
JP2023527153A (ja) 2023-06-27
TW202210081A (zh) 2022-03-16
AU2021273936A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JP6865038B2 (ja) Ｎａｆｌｄおよびｎａｓｈの治療
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP7022136B2 (ja) 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
US20220378802A1 (en) Treatment of alcoholic hepatitis
KR20190044667A (ko) Fxr 작용제의 신규 요법
TWI631943B (zh) 治療脂肪肝疾病之方法
US20230181602A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
US20230181601A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
EP3716975A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
US20020151583A1 (en) Prevention of liver cancer by administration of simvastatin
BR122025021620A2 (pt) Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica